Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

accord healthcare b.v. accord healthcare b.v. - diazepamum - tabletti - 10 mg - diatsepaami

Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

accord healthcare b.v. accord healthcare b.v. - meropenemum trihydricum - injektio/infuusiokuiva-aine, liuosta varten - 500 mg - meropeneemi

Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

accord healthcare b.v. accord healthcare b.v. - meropenemum trihydricum - injektio/infuusiokuiva-aine, liuosta varten - 1 g - meropeneemi

Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - dutasteride, tamsulosin hydrochloride - kapseli, kova - 0,5 mg / 0,4 mg - tamsulosiini ja dutasteridi

Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - daptomycin - injektio-/infuusiokuiva-aine liuosta varten - 350 mg - daptomysiini

Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - daptomycin - injektio-/infuusiokuiva-aine liuosta varten - 500 mg - daptomysiini

Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

viatris limited - klopidogreelibesilata - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentin nousua akuutti sydäninfarkti, yhdessä asa lääketieteellisesti hoitoa saaneilla potilailla oikeutettu liuotushoito. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. lisätietoja, katso kohta 5.

Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogreelin hydrokloridi - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboottiset aineet - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

mylan pharmaceuticals limited - memantiinihydrokloridia - alzheimerin tauti - other anti-dementia drugs, psychoanaleptics, - alzheimerin taudin keskivaikean tai vaikean potilaan hoito.

Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - letrozole - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli